ClearPoint Neuro (NASDAQ:CLPT) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS

ClearPoint Neuro (NASDAQ:CLPT) posted its earnings results on Wednesday. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05), Zacks reports. ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. ClearPoint Neuro updated its FY 2025 guidance to EPS.

ClearPoint Neuro Stock Up 3.0 %

Shares of NASDAQ CLPT traded up $0.50 during trading on Wednesday, hitting $17.22. 239,041 shares of the company traded hands, compared to its average volume of 204,522. The company has a 50-day moving average price of $16.62 and a 200-day moving average price of $13.78. ClearPoint Neuro has a 1 year low of $5.11 and a 1 year high of $19.22. The firm has a market capitalization of $475.01 million, a P/E ratio of -24.96 and a beta of 1.03.

Analysts Set New Price Targets

CLPT has been the subject of several analyst reports. B. Riley boosted their target price on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Lake Street Capital raised their target price on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, January 21st.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.